Life Science

A selective inhibitor of G9a histone methyltransferase (IC₅₀ = 1.7 &muM) less effectively inhibits G9a-like protein (GLP IC₅₀ = 38 &muM) and has no effect on other known histone methyltransferases.

A selective inhibitor of G9a histone methyltransferase (IC₅₀ = 1.7 &muM) less effectively inhibits G9a-like protein (GLP IC₅₀ = 38 &muM) and has no effect on other known histone methyltransferases.

A selective inhibitor of G9a histone methyltransferase (IC₅₀ = 1.7 &muM) less effectively inhibits G9a-like protein (GLP IC₅₀ = 38 &muM) and has no effect on other known histone methyltransferases.

A potent inhibitor of MEK5 (IC₅₀ = 4.3 nM) and moderate inhibitor of ERK5 and TGF&betaR1 (IC₅₀s = 810 and 1800 nM, respectively).

A potent inhibitor of MEK5 (IC₅₀ = 4.3 nM) and moderate inhibitor of ERK5 and TGF&betaR1 (IC₅₀s = 810 and 1800 nM, respectively).

A potent inhibitor of MEK5 (IC₅₀ = 4.3 nM) and moderate inhibitor of ERK5 and TGF&betaR1 (IC₅₀s = 810 and 1800 nM, respectively).

A potent inhibitor of MEK5 (IC₅₀ = 4.3 nM) and moderate inhibitor of ERK5 and TGF&betaR1 (IC₅₀s = 810 and 1800 nM, respectively).

A potent inhibitor of both MEK5 and ERK5 (IC₅₀s = 1.5 and 59 nM, respectively) minimally inhibits a panel of related kinases, including MEK1/2 and ERK1/2 blocks sorbitol-induced phosphorylation of ERK5, without affecting phosphorylation

A potent inhibitor of both MEK5 and ERK5 (IC₅₀s = 1.5 and 59 nM, respectively) minimally inhibits a panel of related kinases, including MEK1/2 and ERK1/2 blocks sorbitol-induced phosphorylation of ERK5, without affecting phosphorylation

An LSD1 inhibitor.

An LSD1 inhibitor.

An LSD1 inhibitor.